RSLS

ReShape Lifesciences Inc. Common Stock NASDAQ Capital Market
$5.84
Open: $6.21 High: $6.66 Low: $5.55 Close: $5.84
Range: 2021-06-23 - 2021-06-24
Volume: 4,362,195
Market: Open
Powered by Finage Stock APIDelayed data
RSLS
ReShape Lifesciences Inc. Common Stock 1001 Calle Amanecer San Clemente CA, 92673 https://www.reshapelifesciences.com
Reshape Lifesciences Inc is a medical device company. The company is focused on the design and development of devices which use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders.
  • CEO: Dan W. Gladney
  • Employees: 83
  • Sector: Healthcare
  • Industry: Medical Devices
RSLS News
Latest news about the RSLS
  • ReShape Lifesciences Closes First Day of Trading on the NASDAQ Capital Market

    Shares of ReShape Lifesciences commenced trading on The Nasdaq Capital Market at market open on June 16, 2021 under the ticker symbol "RSLS"SAN CLEMENTE, CA / ACCESSWIRE / June 17, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, announced that its common stock effectively traded at a first day volume of over 3.

    View More →
  • ReShape Lifesciences Completes Merger with Obalon Therapeutics

    Shares of ReShape Lifesciences to commence trading on The Nasdaq Capital Market on June 16, 2021 under ticker symbol "RSLS"Combination creates opportunity for ReShape to expand portfolio of FDA approved weight loss solutions and reimbursed virtual care servicesSAN CLEMENTE, CA / ACCESSWIRE / June 16, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), a global weight-loss solutions leader, today announced the completion of the previously announced merger with Obalon Therapeutics.

    View More →
  • ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 15, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc.

    View More →
  • ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Update on Status of Pending Merger

    SAN CLEMENTE, CA and SAN DIEGO, CA / ACCESSWIRE / June 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS) and Obalon Therapeutics, Inc.

    View More →
  • Reminder: Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

    SAN DIEGO, CA / ACCESSWIRE / May 24, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc.

    View More →
  • Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

    SAN DIEGO, CA / ACCESSWIRE / May 21, 2021 / Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable gas-filled intragastric balloon system for the treatment of obesity, is taking this opportunity to remind its stockholders to vote on all the proposals related to the proposed merger with ReShape Lifesciences Inc.

    View More →
  • Obalon Therapeutics Stockholders Special Meeting Adjourned to May 25, 2021

    Urging all Shareholders to Vote For Proposals Related to Merger with ReShape LifeSciences Inc.Meeting to be held via Webcast at 8:30 a.

    View More →
  • ReShape Lifesciences Announces First Quarter 2021 Financial and Operational Results

    SAN CLEMENTE, CA / ACCESSWIRE / May 17, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally invasive medical devices to treat obesity and metabolic diseases, today reported its financial and operational results for the three months ended March 31, 2021.

    View More →
  • ReShape Lifesciences Announces Fourth Quarter and Full Year 2020 Financial Results

    SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter and full year ended December 31, 2020.

    View More →
  • Reshape Lifesciences to Report Fourth Quarter and Full Year 2020 Financial and Operational Results on Wednesday, March 10, 2021

    Webinar to discuss results on March 10, 2021 at 4:30 p.TSAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc.

    View More →
  • OBALON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of OBLN and Encourages Investors to Contact the Firm

    NEW YORK, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Obalon Therapeutics, Inc. (NASDAQ: OBLN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ReShape Lifesciences Inc. (Other OTC: RSLS). Click here to learn more and participate in the action. On January 20, 2021, Obalon announced that it had signed an agreement to be acquired by ReShape in an all-stock merger. Pursuant to the merger agreement, at the close of the merger, current Obalon stockholders will own 49% while current ReShape stockholders will own 51% of the combined company. Bragar Eagel & Squire is concerned that Obalon’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Obalon’s stockholders. If you own shares of Obalon and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Melissa Fortunato, Esq.Alexandra Raymond, Esq.investigations@bespc.comwww.bespc.com

    View More →
  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.

    WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. ("ReShape") (OTCQB: RSLS). Under the terms of the merger agreement, ReShape will acquire Obalon in an all-stock transaction, pursuant to which Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol "RSLS." Upon completion of the merger, ReShape stockholders will own approximately 51% of the combined company's outstanding common stock and Obalon stockholders will own approximately 49%.

    View More →
  • ReShape Lifesciences Inc. to Merge With Obalon Therapeutics, Inc. to Expand Weight Loss Product Offering

    SAN CLEMENTE, CA / ACCESSWIRE / January 20, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, announced today that it has entered into a definitive merger agreement with Obalon Therapeutics, Inc.

    View More →
  • ReShape Lifesciences Announces Third Quarter 2020 Financial and Operational Results

    SAN CLEMENTE, CA / ACCESSWIRE / November 12, 2020 / ReShape Lifesciences Inc.

    View More →
  • ReShape Lifesciences to Report Third Quarter 2020 Financial and Operational Results on Thursday, November 12, 2020

    SAN CLEMENTE, CA / ACCESSWIRE / November 10, 2020 / ReShape Lifesciences Inc.

    View More →
  • First Twenty-five Healthcare Professionals Enrolled in ReShapeCare™, a Reimbursable, Evidence-based Virtual Weight Management Program

    ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today announced that the first 25 healthcare providers have partnered with ReShapeCareTM since the program's launch in June of this year, allowing referrals of their patients to the reimbursable, virtual weight-management program.

    View More →
  • ReShape Lifesciences™ Announces Positive Preclinical Results for Its Investigational Diabetes Bloc-Stim Neuromodulation Device

    ReShape Lifesciences Inc., (OTCQB: RSLS) a global weight-loss solutions leader, today announced preclinical research demonstrating the Company's investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) proprietary device for the treatment of type 2 diabetes mellitus (T2DM) was well-tolerated and met the study endpoints. The study was conducted as a part of the National Institutes of Health (NIH) Small Business Innovation Research Phase I grant that was previously awarded August 1, 2019.

    View More →
  • ReShape Lifesciences Announces Second Quarter 2020 Financial and Operational Results

    SAN CLEMENTE, CA / ACCESSWIRE / August 13, 2020 / ReShape Lifesciences Inc.

    View More →
  • ReShape Lifesciences to Report Second Quarter 2020 Financial and Operational Results on Thursday, August 13, 2020

    SAN CLEMENTE, CA / ACCESSWIRE / August 11, 2020 / ReShape Lifesciences Inc.

    View More →
  • ReShape Lifesciences Recognizes National Parents' Day Offering New Resources for Women Considering Weight-Loss and Parenthood

    The minimally-invasive Lap-Band® Procedure is proven to improve fertility and support healthier pregnancies.

    View More →